IBDEI1XR ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30918,1,4,0)
;;=4^N05.3
;;^UTILITY(U,$J,358.3,30918,2)
;;=^5015544
;;^UTILITY(U,$J,358.3,30919,0)
;;=N05.4^^123^1597^44
;;^UTILITY(U,$J,358.3,30919,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30919,1,3,0)
;;=3^Nephritic syndrome unspec w/ diffuse endocaplry prolif glomrlneph
;;^UTILITY(U,$J,358.3,30919,1,4,0)
;;=4^N05.4
;;^UTILITY(U,$J,358.3,30919,2)
;;=^5015545
;;^UTILITY(U,$J,358.3,30920,0)
;;=N05.5^^123^1597^47
;;^UTILITY(U,$J,358.3,30920,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30920,1,3,0)
;;=3^Nephritic syndrome unspec w/ diffuse mesangiocap glomrlneph
;;^UTILITY(U,$J,358.3,30920,1,4,0)
;;=4^N05.5
;;^UTILITY(U,$J,358.3,30920,2)
;;=^5015546
;;^UTILITY(U,$J,358.3,30921,0)
;;=N05.6^^123^1597^42
;;^UTILITY(U,$J,358.3,30921,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30921,1,3,0)
;;=3^Nephritic syndrome unspec w/ dense deposit disease
;;^UTILITY(U,$J,358.3,30921,1,4,0)
;;=4^N05.6
;;^UTILITY(U,$J,358.3,30921,2)
;;=^5015547
;;^UTILITY(U,$J,358.3,30922,0)
;;=N05.7^^123^1597^43
;;^UTILITY(U,$J,358.3,30922,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30922,1,3,0)
;;=3^Nephritic syndrome unspec w/ diffuse crescentic glomrlneph
;;^UTILITY(U,$J,358.3,30922,1,4,0)
;;=4^N05.7
;;^UTILITY(U,$J,358.3,30922,2)
;;=^5015548
;;^UTILITY(U,$J,358.3,30923,0)
;;=N05.8^^123^1597^50
;;^UTILITY(U,$J,358.3,30923,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30923,1,3,0)
;;=3^Nephritic syndrome unspec w/ oth morphologic changes
;;^UTILITY(U,$J,358.3,30923,1,4,0)
;;=4^N05.8
;;^UTILITY(U,$J,358.3,30923,2)
;;=^5134085
;;^UTILITY(U,$J,358.3,30924,0)
;;=N05.9^^123^1597^51
;;^UTILITY(U,$J,358.3,30924,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30924,1,3,0)
;;=3^Nephritic syndrome unspec w/ unspec morphologic changes
;;^UTILITY(U,$J,358.3,30924,1,4,0)
;;=4^N05.9
;;^UTILITY(U,$J,358.3,30924,2)
;;=^5134086
;;^UTILITY(U,$J,358.3,30925,0)
;;=N06.0^^123^1597^39
;;^UTILITY(U,$J,358.3,30925,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30925,1,3,0)
;;=3^Isolated proteinuria w/ minor glomerular abnormality
;;^UTILITY(U,$J,358.3,30925,1,4,0)
;;=4^N06.0
;;^UTILITY(U,$J,358.3,30925,2)
;;=^5015549
;;^UTILITY(U,$J,358.3,30926,0)
;;=N06.1^^123^1597^38
;;^UTILITY(U,$J,358.3,30926,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30926,1,3,0)
;;=3^Isolated proteinuria w/ focal & segmental glomerular lesions
;;^UTILITY(U,$J,358.3,30926,1,4,0)
;;=4^N06.1
;;^UTILITY(U,$J,358.3,30926,2)
;;=^5015550
;;^UTILITY(U,$J,358.3,30927,0)
;;=N06.2^^123^1597^35
;;^UTILITY(U,$J,358.3,30927,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30927,1,3,0)
;;=3^Isolated proteinuria w/ diffuse membranous glomerulonephritis
;;^UTILITY(U,$J,358.3,30927,1,4,0)
;;=4^N06.2
;;^UTILITY(U,$J,358.3,30927,2)
;;=^5015551
;;^UTILITY(U,$J,358.3,30928,0)
;;=N06.3^^123^1597^36
;;^UTILITY(U,$J,358.3,30928,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30928,1,3,0)
;;=3^Isolated proteinuria w/ diffuse mesangial prolif glomrlneph
;;^UTILITY(U,$J,358.3,30928,1,4,0)
;;=4^N06.3
;;^UTILITY(U,$J,358.3,30928,2)
;;=^5015552
;;^UTILITY(U,$J,358.3,30929,0)
;;=N06.4^^123^1597^34
;;^UTILITY(U,$J,358.3,30929,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30929,1,3,0)
;;=3^Isolated proteinuria w/ diffuse endocaplry prolif glomrlneph
;;^UTILITY(U,$J,358.3,30929,1,4,0)
;;=4^N06.4
;;^UTILITY(U,$J,358.3,30929,2)
;;=^5015553
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XR 3767 printed Nov 22, 2024@17:28:02 Page 2
IBDEI1XR ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30918,1,4,0)
+2 ;;=4^N05.3
+3 ;;^UTILITY(U,$J,358.3,30918,2)
+4 ;;=^5015544
+5 ;;^UTILITY(U,$J,358.3,30919,0)
+6 ;;=N05.4^^123^1597^44
+7 ;;^UTILITY(U,$J,358.3,30919,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,30919,1,3,0)
+10 ;;=3^Nephritic syndrome unspec w/ diffuse endocaplry prolif glomrlneph
+11 ;;^UTILITY(U,$J,358.3,30919,1,4,0)
+12 ;;=4^N05.4
+13 ;;^UTILITY(U,$J,358.3,30919,2)
+14 ;;=^5015545
+15 ;;^UTILITY(U,$J,358.3,30920,0)
+16 ;;=N05.5^^123^1597^47
+17 ;;^UTILITY(U,$J,358.3,30920,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,30920,1,3,0)
+20 ;;=3^Nephritic syndrome unspec w/ diffuse mesangiocap glomrlneph
+21 ;;^UTILITY(U,$J,358.3,30920,1,4,0)
+22 ;;=4^N05.5
+23 ;;^UTILITY(U,$J,358.3,30920,2)
+24 ;;=^5015546
+25 ;;^UTILITY(U,$J,358.3,30921,0)
+26 ;;=N05.6^^123^1597^42
+27 ;;^UTILITY(U,$J,358.3,30921,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,30921,1,3,0)
+30 ;;=3^Nephritic syndrome unspec w/ dense deposit disease
+31 ;;^UTILITY(U,$J,358.3,30921,1,4,0)
+32 ;;=4^N05.6
+33 ;;^UTILITY(U,$J,358.3,30921,2)
+34 ;;=^5015547
+35 ;;^UTILITY(U,$J,358.3,30922,0)
+36 ;;=N05.7^^123^1597^43
+37 ;;^UTILITY(U,$J,358.3,30922,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,30922,1,3,0)
+40 ;;=3^Nephritic syndrome unspec w/ diffuse crescentic glomrlneph
+41 ;;^UTILITY(U,$J,358.3,30922,1,4,0)
+42 ;;=4^N05.7
+43 ;;^UTILITY(U,$J,358.3,30922,2)
+44 ;;=^5015548
+45 ;;^UTILITY(U,$J,358.3,30923,0)
+46 ;;=N05.8^^123^1597^50
+47 ;;^UTILITY(U,$J,358.3,30923,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,30923,1,3,0)
+50 ;;=3^Nephritic syndrome unspec w/ oth morphologic changes
+51 ;;^UTILITY(U,$J,358.3,30923,1,4,0)
+52 ;;=4^N05.8
+53 ;;^UTILITY(U,$J,358.3,30923,2)
+54 ;;=^5134085
+55 ;;^UTILITY(U,$J,358.3,30924,0)
+56 ;;=N05.9^^123^1597^51
+57 ;;^UTILITY(U,$J,358.3,30924,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,30924,1,3,0)
+60 ;;=3^Nephritic syndrome unspec w/ unspec morphologic changes
+61 ;;^UTILITY(U,$J,358.3,30924,1,4,0)
+62 ;;=4^N05.9
+63 ;;^UTILITY(U,$J,358.3,30924,2)
+64 ;;=^5134086
+65 ;;^UTILITY(U,$J,358.3,30925,0)
+66 ;;=N06.0^^123^1597^39
+67 ;;^UTILITY(U,$J,358.3,30925,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,30925,1,3,0)
+70 ;;=3^Isolated proteinuria w/ minor glomerular abnormality
+71 ;;^UTILITY(U,$J,358.3,30925,1,4,0)
+72 ;;=4^N06.0
+73 ;;^UTILITY(U,$J,358.3,30925,2)
+74 ;;=^5015549
+75 ;;^UTILITY(U,$J,358.3,30926,0)
+76 ;;=N06.1^^123^1597^38
+77 ;;^UTILITY(U,$J,358.3,30926,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,30926,1,3,0)
+80 ;;=3^Isolated proteinuria w/ focal & segmental glomerular lesions
+81 ;;^UTILITY(U,$J,358.3,30926,1,4,0)
+82 ;;=4^N06.1
+83 ;;^UTILITY(U,$J,358.3,30926,2)
+84 ;;=^5015550
+85 ;;^UTILITY(U,$J,358.3,30927,0)
+86 ;;=N06.2^^123^1597^35
+87 ;;^UTILITY(U,$J,358.3,30927,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,30927,1,3,0)
+90 ;;=3^Isolated proteinuria w/ diffuse membranous glomerulonephritis
+91 ;;^UTILITY(U,$J,358.3,30927,1,4,0)
+92 ;;=4^N06.2
+93 ;;^UTILITY(U,$J,358.3,30927,2)
+94 ;;=^5015551
+95 ;;^UTILITY(U,$J,358.3,30928,0)
+96 ;;=N06.3^^123^1597^36
+97 ;;^UTILITY(U,$J,358.3,30928,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,30928,1,3,0)
+100 ;;=3^Isolated proteinuria w/ diffuse mesangial prolif glomrlneph
+101 ;;^UTILITY(U,$J,358.3,30928,1,4,0)
+102 ;;=4^N06.3
+103 ;;^UTILITY(U,$J,358.3,30928,2)
+104 ;;=^5015552
+105 ;;^UTILITY(U,$J,358.3,30929,0)
+106 ;;=N06.4^^123^1597^34
+107 ;;^UTILITY(U,$J,358.3,30929,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,30929,1,3,0)
+110 ;;=3^Isolated proteinuria w/ diffuse endocaplry prolif glomrlneph
+111 ;;^UTILITY(U,$J,358.3,30929,1,4,0)
+112 ;;=4^N06.4
+113 ;;^UTILITY(U,$J,358.3,30929,2)
+114 ;;=^5015553
